Category
8 articles
Reports of muscle loss and reduced gym performance circulate widely among finasteride users online, but the clinical picture is considerably more nuanced than forum discussions suggest. Understanding the hormonal mechanisms at play—and the evidence-based adjustments that can protect body composition—gives men a more accurate framework for evaluating this concern.
Hair transplant surgery and finasteride therapy are often discussed as separate paths, but leading dermatologists increasingly treat them as complementary tools within a single, coordinated strategy. Understanding when to start finasteride relative to a transplant procedure — and how each intervention supports the other — can meaningfully influence long-term outcomes. This clinical overview breaks down the science behind combining medical and surgical hair restoration.
Millions of American men take generic finasteride rather than brand-name Propecia, primarily because the cost difference is substantial. But questions about bioavailability, manufacturing consistency, and real-world outcomes persist among patients and clinicians alike. This article breaks down what the FDA's equivalency framework actually means, examines where legitimate concerns exist, and helps cost-conscious readers make an informed decision about which formulation belongs in their medicine c
The decision to start finasteride at 23 looks very different from making that same choice at 52. Age shapes everything from treatment efficacy and side effect risk to long-term commitment expectations—and the clinical evidence reflects that complexity in ways patients deserve to understand before starting therapy.
Most men taking finasteride for hair loss have never questioned whether their dose is actually optimal. A closer look at the clinical literature reveals meaningful differences between standard 1mg and off-label 5mg protocols — differences that may influence outcomes in ways dermatologists don't always discuss at the point of prescription.
Few topics generate more online debate than finasteride's potential impact on sexual function. This article cuts through the noise by examining actual clinical trial incidence rates, the documented role of the nocebo effect, and what men considering finasteride should genuinely weigh before making a treatment decision.
Finasteride has been FDA-approved for male pattern baldness since 1997, yet a surprising number of US dermatologists remain reluctant to recommend it as a first-line treatment. The reasons behind that hesitation — ranging from liability exposure to financial incentives — deserve a candid examination. Understanding the gap between clinical evidence and prescribing behavior can help patients advocate more effectively for themselves.
When it comes to treating male pattern baldness, finasteride and minoxidil are the two most clinically validated options available in the United States. Understanding how they differ in mechanism, efficacy, side effect profiles, and long-term commitment can make the difference between a treatment plan that works and one that falls short. This guide breaks down everything you need to know before making your first move.